In a two-part financing, Aposense raised $6 million in September 2007 and now concluded the second part of additional $7.3 million. A prominent group of existing shareholders participated in the financing by exercising outstanding warrants, in exchange for shares of Aposense.
Participating shareholders included, among others, Zeigler Meditech Equity Partners LP, Pontifax LP, Docor International, Federman Holdings, Technorov, Bargal R&D Investment, Phoenix Insurance Co, Polar Investments and Clal Biotechnology Industries.
Yoram Ashery, CEO of Aposense, said: “Our new name, Aposense, reflects our expanded mission to improve patient care through both molecular imaging and targeted therapy based on our apoptosis targeting technology.
“This $13 million financing will help fulfill this mission by funding operations into Phase III clinical trials of our ML-10 compound, for molecular imaging of apoptosis. I would like to thank the shareholders who participated in this financing for their contribution and continued support.”